All In Biotech

Drug Trial Radar · NCT06226545

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

41

Actual

Start

Mar 5, 2024

Primary completion

Apr 22, 2025

Study completion Apr 22, 2025

Sponsor

Lead sponsor
Lassen Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jan 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED). The primary and secondary objectives of this study are to evaluate the treatment effect, safety, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.

Conditions

  • Thyroid Eye Disease
  • Graves Ophthalmopathy
  • Graves Orbitopathy
  • Thyroid Associated Ophthalmopathy
  • Endocrine System Diseases
  • Orbital Diseases
  • Proptosis
  • Eye Diseases

Interventions

  • LASN01Drug

    Low dose of LASN01 will be administered intravenously.

  • LASN01Drug

    High dose of LASN01 will be administered intravenously.

  • PlaceboDrug

    Placebo will be administered intravenously.

  • LASN01Drug

    High dose of LASN01 will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Showing a Response in Proptosis Measured Using Hertel Exophthalmometer (≥2 mm Decrease From Baseline) in the Study Eye and Separately in Either Eye Without Increased Proptosis (≥2 mm Increase) in the Other EyeTime frame: Day 1-Day 253
  2. For Randomized Treatment Arms: Number of Participants With Adverse Events Receiving LASN01 Compared to PlaceboTime frame: Day 1-Day 393
  3. For Open-label Treatment Arm: Number of Participants With Adverse Events Receiving LASN01Time frame: Day 1-Day 393

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • Site 111

    Beverly Hills, California

  • Site 105

    Palo Alto, California

  • Site 101

    San Diego, California

  • Site 103

    Miami, Florida

  • Site 108

    Livonia, Michigan

  • Site 112

    Las Vegas, Nevada

  • Site 110

    Wilmington, North Carolina

  • Site 106

    Houston, Texas

  • Site 104

    Houston, Texas

  • Site 109

    Seattle, Washington

  • Site 302

    Córdoba, Spain

  • Site 301

    Seville, Spain

  • Site 201

    London, United Kingdom

  • Site 206

    London, United Kingdom

  • Site 204

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.